Photocure ASA
OB:PHO Rapporto sulle azioni
Cap. di mercato: NOK 1.5b
Photocure Salute del bilancio
Salute finanziaria criteri di controllo 6/6 Photocure ha un patrimonio netto totale di NOK499.7M e un debito totale di NOK0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente NOK713.6M e NOK213.9M. L'EBIT di Photocure è NOK40.0M rendendo il suo rapporto di copertura degli interessi 2.4. Ha liquidità e investimenti a breve termine pari a NOK267.0M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi 2.4x Contanti NOK 266.99m Patrimonio netto NOK 499.67m Totale passività NOK 213.92m Totale attività NOK 713.58m
Aggiornamenti recenti sulla salute finanziaria
Mostra tutti gli aggiornamenti
Consensus EPS estimates fall by 17% Nov 06
We Think Photocure's (OB:PHO) Robust Earnings Are Conservative Aug 14
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 08
Consensus EPS estimates increase from loss to kr0.019 profit Jul 19
Photocure ASA's (OB:PHO) P/S Still Appears To Be Reasonable Jun 01
Photocure ASA Announces Board Appointments May 25
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 17 Photocure ASA Reiterates Financial Guidance for the Year 2024 May 16
Consensus EPS estimates fall from profit to kr0.58 loss May 12
Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence Apr 30
Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy Mar 29
Consensus EPS estimates increase by 50%, revenue downgraded Feb 28
Price target decreased by 7.0% to kr86.00 Feb 25
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 22
Forecast breakeven date pushed back to 2025 Feb 22 Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024
Photocure ASA's (OB:PHO) 26% Jump Shows Its Popularity With Investors Dec 18
Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China Nov 29
Third quarter 2023 earnings released: kr0.18 loss per share (vs kr0.37 loss in 3Q 2022) Nov 09
Photocure ASA Announces Change of Board Composition Sep 28
Director recently bought kr6.5m worth of stock Sep 05
Potential Upside For Photocure ASA (OB:PHO) Not Without Risk Sep 01
Price target decreased by 10.0% to kr90.00 Aug 14
Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint Aug 12
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 10
Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China Jul 07
Insufficient new directors Jul 02
Consensus estimates of losses per share improve by 15% May 07
Full year 2022 earnings: EPS and revenues miss analyst expectations Apr 14
Time To Worry? Analysts Just Downgraded Their Photocure ASA (OB:PHO) Outlook Mar 01
Price target decreased by 7.7% to kr120 Feb 25
Forecast breakeven date pushed back to 2024 Feb 25
Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021) Feb 24
Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC Feb 20
Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week Jan 05
Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week Jan 04 Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023
Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy Dec 05
Price target decreased to kr125 Nov 07
Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021) Nov 07
Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc Oct 06
PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S Sep 28
Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology Sep 20
Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy Sep 08
Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development Sep 01
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 11
Price target decreased to kr135 Aug 03
Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States Jul 28
Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki Jun 13
Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022. Jun 04
President & CEO exercised options to buy kr10m worth of stock. Jun 03
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 13
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 08
Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand Mar 06
Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model Feb 28
Full year 2021 earnings: EPS and revenues exceed analyst expectations Feb 24
Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S Feb 07
Consensus EPS estimates fall to -kr0.53 Nov 27
Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020) Nov 18
Insider exercised options to buy kr2.8m worth of stock. Aug 31
Consensus EPS estimates fall to -kr0.53 Aug 18
Analyst Estimates: Here's What Brokers Think Of Photocure ASA (OB:PHO) After Its Second-Quarter Report Aug 14
We Think Photocure (OB:PHO) Can Stay On Top Of Its Debt Aug 12
Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020) Aug 12
Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology Jun 25
Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira) Jun 22
President & CEO exercised options to buy kr2.8m worth of stock. Jun 10
Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020. Mar 28
Photocure ASA Suspends Guidance for 2023 Mar 04
Analysts lower EPS estimates to kr0.94 Mar 03
New 90-day high: kr118 Mar 01
Do Institutions Own Photocure ASA (OB:PHO) Shares? Feb 11
New 90-day high: kr109 Feb 06 Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021
Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan Jan 28
Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan Jan 26
Photocure ASA's (OB:PHO) Stock Is Going Strong: Have Financials A Role To Play? Jan 21
The Photocure (OB:PHO) Share Price Is Up 286% And Shareholders Are Boasting About It Dec 31
New 90-day high: kr100.00 Dec 28
We're Not So Sure You Should Rely on Photocure's (OB:PHO) Statutory Earnings Dec 09
Key Executive exercised options to buy kr1.0m worth of stock. Dec 02
Is Photocure (OB:PHO) Using Too Much Debt? Nov 19
Price target raised to kr150 Nov 19
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( NOK387.6M ) di PHO superano le sue passività a breve termine ( NOK66.7M ).
Passività a lungo termine: Le attività a breve termine di PHO ( NOK387.6M ) superano le sue passività a lungo termine ( NOK147.3M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: PHO è esente da debiti.
Riduzione del debito: PHO non aveva debiti 5 anni fa.
Copertura del debito: PHO non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo .
Copertura degli interessi: PHO non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
